Moore Capital Management LP Sells 52,475 Shares of Teleflex Incorporated $TFX

Moore Capital Management LP decreased its stake in Teleflex Incorporated (NYSE:TFX) by 50.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 52,175 shares of the medical technology company’s stock after selling 52,475 shares during the quarter. Moore Capital Management LP owned 0.12% of Teleflex worth $6,614,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TFX. BlackRock Inc. acquired a new position in shares of Teleflex during the 2nd quarter worth about $688,537,000. Jupiter Topco LLC bought a new position in Teleflex during the 2nd quarter worth approximately $550,456,000. Janus Henderson Group PLC boosted its stake in Teleflex by 1.1% during the 1st quarter. Janus Henderson Group PLC now owns 4,291,311 shares of the medical technology company’s stock worth $513,281,000 after acquiring an additional 45,199 shares during the last quarter. AQR Capital Management LLC grew its holdings in Teleflex by 478.1% during the third quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company’s stock valued at $287,603,000 after purchasing an additional 1,956,811 shares during the period. Finally, State Street Corp grew its holdings in Teleflex by 1.5% during the fourth quarter. State Street Corp now owns 1,478,776 shares of the medical technology company’s stock valued at $180,470,000 after purchasing an additional 22,111 shares during the period. Institutional investors own 95.62% of the company’s stock.

Teleflex Price Performance

TFX stock opened at $139.81 on Monday. The stock has a 50-day moving average price of $133.86 and a two-hundred day moving average price of $126.05. The stock has a market cap of $5.92 billion, a PE ratio of -6.00, a price-to-earnings-growth ratio of 0.93 and a beta of 0.81. The company has a current ratio of 2.60, a quick ratio of 2.12 and a debt-to-equity ratio of 0.94. Teleflex Incorporated has a 1 year low of $100.18 and a 1 year high of $145.00.

Teleflex (NYSE:TFX) last released its quarterly earnings results on Thursday, August 6th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.48. The firm had revenue of $570.33 million for the quarter, compared to the consensus estimate of $559.59 million. Teleflex had a positive return on equity of 11.93% and a negative net margin of 39.67%.The company’s revenue for the quarter was up 28.9% on a year-over-year basis. During the same quarter last year, the business posted $3.73 EPS. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. Equities analysts forecast that Teleflex Incorporated will post 7.26 EPS for the current fiscal year.

Teleflex Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Friday, August 14th will be given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Friday, August 14th. Teleflex’s dividend payout ratio (DPR) is currently -5.84%.

Wall Street Analysts Forecast Growth

TFX has been the topic of a number of recent analyst reports. Raymond James Financial reissued an “outperform” rating and set a $150.00 price target on shares of Teleflex in a research report on Friday, May 8th. Royal Bank Of Canada upgraded shares of Teleflex from a “sector perform” rating to an “outperform” rating and upped their price objective for the company from $135.00 to $155.00 in a research report on Friday, May 8th. Truist Financial raised their price objective on Teleflex from $143.00 to $150.00 and gave the stock a “hold” rating in a research note on Monday, August 10th. Wells Fargo & Company lifted their target price on Teleflex from $130.00 to $138.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Finally, Needham & Company LLC boosted their target price on Teleflex from $159.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, August 25th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $152.90.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.